Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Alrizomadlin

Generic Name: Alrizomadlin

Drug Type: Small Molecule

Chemical Formula: C_₃₄H_₃₈Cl_₂FN_₃O_₄

CAS Number: 1818393-16-6

Unique Ingredient Identifier: 15QAU0SI9J

Overview

Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.

Background

Alrizomadlin is a novel MDM2 inhibitor that blocks the interaction of MDM2 and p53. It is being investigated in cancers.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

Phase 1

Not yet recruiting

Posted: 2024/12/16

Sponsor:

AeRang Kim

ID:NCT06735820

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Phase 2

Not yet recruiting

Posted: 2024/10/23

Sponsor:National Cancer Inst...

ID:NCT06654050

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Phase 1

Recruiting

Posted: 2023/01/27

Sponsor:Ascentage Pharma Gro...

ID:NCT05701306

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Phase 1

Recruiting

Posted: 2021/03/05

Sponsor:Ascentage Pharma Gro...

ID:NCT04785196

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Phase 2

Recruiting

Posted: 2020/08/03

Sponsor:Ascentage Pharma Gro...

ID:NCT04496349

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development

2 months ago

Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.

Olverembatinib Receives Third Breakthrough Therapy Designation in China for Ph+ ALL Treatment

3 months ago

Ascentage Pharma's olverembatinib has received Breakthrough Therapy Designation from China's NMPA for first-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy